Ischemia and infarction in STEMI patients with multivessel disease: Insights from the CvLPRIT Nuclear Substudy

Andrew D. Kelion; Mini V. Pakkal; Fahmid U. Chowdhury; James D. Birchall; Katherine L. Dixon; Florence Y. Lai; Damian J. Kelly; Marcus Flather; Gerry P. McCann; Anthony H. Gershlick

doi:10.1016/j.jacc.2016.03.544

Ischemia and infarction in STEMI patients with multivessel disease: Insights from the CvLPRIT Nuclear Substudy

Andrew D. Kelion (Lead Author), Mini V. Pakkal, Fahmid U. Chowdhury, James D. Birchall, Katherine L. Dixon, Florence Y. Lai, Damian J. Kelly, Marcus Flather, Gerry P. McCann, Anthony H. Gershlick

Research output: Contribution to journal › Article › peer-review

5 Citations (Scopus)

3 Downloads (Pure)

Abstract

The CvLPRIT (Complete versus Lesion-only PRimary PCI Trial) trial was undertaken in 7 UK centers (1,2). Patients with ST-segment elevation myocardial infarction (STEMI) and multivessel coronary stenoses were randomized to primary percutaneous coronary intervention (PPCI) to the infarct-related artery (IRA) only, or complete revascularization. At 12-month follow-up, the rate of the combined primary endpoint (all-cause mortality, recurrent MI, heart failure, ischemia-driven revascularization) was lower after complete revascularization. All surviving patients were asked to undergo myocardial perfusion scintigraphy (MPS) 6 to 8 weeks post-admission. It was expected that this a priori nuclear substudy would provide mechanistic insights into the outcome of the main trial, and help to define the clinical role of MPS in the PPCI era.

Original language	English
Pages (from-to)	2698-2699
Number of pages	2
Journal	Journal of the American College of Cardiology
Volume	67
Issue number	22
DOIs	https://doi.org/10.1016/j.jacc.2016.03.544
Publication status	Published - 7 Jun 2016

Access to Document

10.1016/j.jacc.2016.03.544Licence: Other

CvLPRIT Nuclear Substudy manuscript for research letter 10-03-16Accepted author manuscript, 354 KBLicence: CC BY-NC-ND

Cite this

Kelion, A. D., Pakkal, M. V., Chowdhury, F. U., Birchall, J. D., Dixon, K. L., Lai, F. Y., Kelly, D. J., Flather, M., McCann, G. P., & Gershlick, A. H. (2016). Ischemia and infarction in STEMI patients with multivessel disease: Insights from the CvLPRIT Nuclear Substudy. Journal of the American College of Cardiology, 67(22), 2698-2699. https://doi.org/10.1016/j.jacc.2016.03.544

Kelion, Andrew D. ; Pakkal, Mini V. ; Chowdhury, Fahmid U. ; Birchall, James D. ; Dixon, Katherine L. ; Lai, Florence Y. ; Kelly, Damian J. ; Flather, Marcus ; McCann, Gerry P. ; Gershlick, Anthony H. / Ischemia and infarction in STEMI patients with multivessel disease: Insights from the CvLPRIT Nuclear Substudy. In: Journal of the American College of Cardiology. 2016 ; Vol. 67, No. 22. pp. 2698-2699.

@article{20c4e46574a9453ab4569aa19780ce0e,

title = "Ischemia and infarction in STEMI patients with multivessel disease: Insights from the CvLPRIT Nuclear Substudy",

abstract = "The CvLPRIT (Complete versus Lesion-only PRimary PCI Trial) trial was undertaken in 7 UK centers (1,2). Patients with ST-segment elevation myocardial infarction (STEMI) and multivessel coronary stenoses were randomized to primary percutaneous coronary intervention (PPCI) to the infarct-related artery (IRA) only, or complete revascularization. At 12-month follow-up, the rate of the combined primary endpoint (all-cause mortality, recurrent MI, heart failure, ischemia-driven revascularization) was lower after complete revascularization. All surviving patients were asked to undergo myocardial perfusion scintigraphy (MPS) 6 to 8 weeks post-admission. It was expected that this a priori nuclear substudy would provide mechanistic insights into the outcome of the main trial, and help to define the clinical role of MPS in the PPCI era.",

author = "Kelion, {Andrew D.} and Pakkal, {Mini V.} and Chowdhury, {Fahmid U.} and Birchall, {James D.} and Dixon, {Katherine L.} and Lai, {Florence Y.} and Kelly, {Damian J.} and Marcus Flather and McCann, {Gerry P.} and Gershlick, {Anthony H.}",

year = "2016",

month = jun,

day = "7",

doi = "10.1016/j.jacc.2016.03.544",

language = "English",

volume = "67",

pages = "2698--2699",

journal = "Journal of the American College of Cardiology",

issn = "0735-1097",

publisher = "Elsevier",

number = "22",

}

Ischemia and infarction in STEMI patients with multivessel disease: Insights from the CvLPRIT Nuclear Substudy. / Kelion, Andrew D. (Lead Author); Pakkal, Mini V.; Chowdhury, Fahmid U.; Birchall, James D.; Dixon, Katherine L.; Lai, Florence Y.; Kelly, Damian J.; Flather, Marcus; McCann, Gerry P.; Gershlick, Anthony H.

In: Journal of the American College of Cardiology, Vol. 67, No. 22, 07.06.2016, p. 2698-2699.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Ischemia and infarction in STEMI patients with multivessel disease: Insights from the CvLPRIT Nuclear Substudy

AU - Kelion, Andrew D.

AU - Pakkal, Mini V.

AU - Chowdhury, Fahmid U.

AU - Birchall, James D.

AU - Dixon, Katherine L.

AU - Lai, Florence Y.

AU - Kelly, Damian J.

AU - Flather, Marcus

AU - McCann, Gerry P.

AU - Gershlick, Anthony H.

PY - 2016/6/7

Y1 - 2016/6/7

N2 - The CvLPRIT (Complete versus Lesion-only PRimary PCI Trial) trial was undertaken in 7 UK centers (1,2). Patients with ST-segment elevation myocardial infarction (STEMI) and multivessel coronary stenoses were randomized to primary percutaneous coronary intervention (PPCI) to the infarct-related artery (IRA) only, or complete revascularization. At 12-month follow-up, the rate of the combined primary endpoint (all-cause mortality, recurrent MI, heart failure, ischemia-driven revascularization) was lower after complete revascularization. All surviving patients were asked to undergo myocardial perfusion scintigraphy (MPS) 6 to 8 weeks post-admission. It was expected that this a priori nuclear substudy would provide mechanistic insights into the outcome of the main trial, and help to define the clinical role of MPS in the PPCI era.

AB - The CvLPRIT (Complete versus Lesion-only PRimary PCI Trial) trial was undertaken in 7 UK centers (1,2). Patients with ST-segment elevation myocardial infarction (STEMI) and multivessel coronary stenoses were randomized to primary percutaneous coronary intervention (PPCI) to the infarct-related artery (IRA) only, or complete revascularization. At 12-month follow-up, the rate of the combined primary endpoint (all-cause mortality, recurrent MI, heart failure, ischemia-driven revascularization) was lower after complete revascularization. All surviving patients were asked to undergo myocardial perfusion scintigraphy (MPS) 6 to 8 weeks post-admission. It was expected that this a priori nuclear substudy would provide mechanistic insights into the outcome of the main trial, and help to define the clinical role of MPS in the PPCI era.

U2 - 10.1016/j.jacc.2016.03.544

DO - 10.1016/j.jacc.2016.03.544

M3 - Article

VL - 67

SP - 2698

EP - 2699

JO - Journal of the American College of Cardiology

JF - Journal of the American College of Cardiology

SN - 0735-1097

IS - 22

ER -